Loading...
Header Logo
Keywords
Last Name
Institution

Professor Henry Wilke Murray

Title[no position]
Institution[no institution name]
Address[no address]
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Murray HW, Luster AD, Zheng H, Ma X. Gamma Interferon-Regulated Chemokines in Leishmania donovani Infection in the Liver. Infect Immun. 2017 Jan; 85(1). PMID: 27795366.
      View in: PubMed
    2. Murray HW, Mitchell-Flack M, Taylor GA, Ma X. IFN-?-induced macrophage antileishmanial mechanisms in mice: A role for immunity-related GTPases, Irgm1 and Irgm3, in Leishmania donovani infection in the liver. Exp Parasitol. 2015 Oct; 157:103-9. PMID: 26208780; PMCID: PMC4640457 [Available on 10/01/16].
    3. Murray HW, Mitchell-Flack M, Zheng H, Ma X. Granzyme-mediated regulation of host defense in the liver in experimental Leishmania donovani infection. Infect Immun. 2015 Feb; 83(2):702-12. PMID: 25452549; PMCID: PMC4294235.
    4. Douvoyiannis M, Khromachou T, Byers N, Hargreaves J, Murray HW. Cutaneous leishmaniasis in North Dakota. Clin Infect Dis. 2014 Sep 01; 59(5):e73-5. PMID: 24850800.
      View in: PubMed
    5. Murray HW, Zhang Y, Zhang Y, Raman VS, Reed SG, Ma X. Regulatory actions of Toll-like receptor 2 (TLR2) and TLR4 in Leishmania donovani infection in the liver. Infect Immun. 2013 Jul; 81(7):2318-26. PMID: 23589575; PMCID: PMC3697629.
    6. Murray HW. Leishmaniasis in the United States: treatment in 2012. Am J Trop Med Hyg. 2012 Mar; 86(3):434-40. PMID: 22403313; PMCID: PMC3284358.
    7. Fusco DN, Downs JA, Satlin MJ, Pahuja M, Ramos L, Barie PS, Fleckenstein L, Murray HW. Non-oral treatment with ivermectin for disseminated strongyloidiasis. Am J Trop Med Hyg. 2010 Oct; 83(4):879-83. PMID: 20889884; PMCID: PMC2946761.
    8. Murray HW. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India. Future Microbiol. 2010 Sep; 5(9):1301-3. PMID: 20860475.
      View in: PubMed
    9. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med. 2010 Feb 11; 362(6):504-12. PMID: 20147716.
      View in: PubMed
    10. Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis. 2008 Oct 15; 47(8):1000-6. PMID: 18781879.
      View in: PubMed
    11. Murray HW. Accelerated control of visceral Leishmania donovani infection in interleukin-6-deficient mice. Infect Immun. 2008 Sep; 76(9):4088-91. PMID: 18573898; PMCID: PMC2519417.
    12. Sundar S, Chakravarty J, Rai VK, Agrawal N, Singh SP, Chauhan V, Murray HW. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clin Infect Dis. 2007 Sep 01; 45(5):556-61. PMID: 17682988.
      View in: PubMed
    13. Murray HW, Tsai CW, Liu J, Ma X. Responses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18. Infect Immun. 2006 Jul; 74(7):4370-4. PMID: 16790814; PMCID: PMC1489747.
    14. Murray HW, Xiang Z, Ma X. Responses to Leishmania donovani in mice deficient in both phagocyte oxidase and inducible nitric oxide synthase. Am J Trop Med Hyg. 2006 Jun; 74(6):1013-5. PMID: 16760512.
      View in: PubMed
    15. Murray HW, Tsai CW, Liu J, Ma X. Visceral Leishmania donovani infection in interleukin-13-/- mice. Infect Immun. 2006 Apr; 74(4):2487-90. PMID: 16552085; PMCID: PMC1418934.
    16. Sundar S, Maurya R, Singh RK, Bharti K, Chakravarty J, Parekh A, Rai M, Kumar K, Murray HW. Rapid, noninvasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of anti-K39 antibody. J Clin Microbiol. 2006 Jan; 44(1):251-3. PMID: 16390983; PMCID: PMC1351954.
    17. Carter KC, Hutchison S, Boitelle A, Murray HW, Sundar S, Mullen AB. Sodium stibogluconate resistance in Leishmania donovani correlates with greater tolerance to macrophage antileishmanial responses and trivalent antimony therapy. Parasitology. 2005 Dec; 131(Pt 6):747-57. PMID: 16336728.
      View in: PubMed
    18. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet. 2005 Oct 29-Nov 4; 366(9496):1561-77. PMID: 16257344.
      View in: PubMed
    19. Murray HW, Flanders KC, Donaldson DD, Sypek JP, Gotwals PJ, Liu J, Ma X. Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis. Infect Immun. 2005 Jul; 73(7):3903-11. PMID: 15972476; PMCID: PMC1168607.
    20. Sundar S, Murray HW. Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ. 2005 May; 83(5):394-5. PMID: 15976883; PMCID: PMC2626237.
    21. Murray HW. Prevention of relapse after chemotherapy in a chronic intracellular infection: mechanisms in experimental visceral leishmaniasis. J Immunol. 2005 Apr 15; 174(8):4916-23. PMID: 15814719.
      View in: PubMed
    22. Murray HW. Interleukin 10 receptor blockade--pentavalent antimony treatment in experimental visceral leishmaniasis. Acta Trop. 2005 Mar; 93(3):295-301. PMID: 15716043.
      View in: PubMed
    23. Murray HW. Treatment of visceral leishmaniasis in 2004. Am J Trop Med Hyg. 2004 Dec; 71(6):787-94. PMID: 15642973.
      View in: PubMed
    24. Amprey JL, Im JS, Turco SJ, Murray HW, Illarionov PA, Besra GS, Porcelli SA, Späth GF. A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan. J Exp Med. 2004 Oct 04; 200(7):895-904. PMID: 15466622; PMCID: PMC2213292.
    25. Kambili C, Murray HW, Golightly LM. Malaria: 30 years of experience at a New York City teaching hospital. Am J Trop Med Hyg. 2004 Apr; 70(4):408-11. PMID: 15100455.
      View in: PubMed
    26. Murray HW. Progress in the treatment of a neglected infectious disease: visceral leishmaniasis. Expert Rev Anti Infect Ther. 2004 Apr; 2(2):279-92. PMID: 15482193.
      View in: PubMed
    27. Davis AJ, Murray HW, Handman E. Drugs against leishmaniasis: a synergy of technology and partnerships. Trends Parasitol. 2004 Feb; 20(2):73-6. PMID: 14747020.
      View in: PubMed
    28. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis. 2004 Feb 01; 38(3):377-83. PMID: 14727208.
      View in: PubMed
    29. Murray HW, Lu CM, Brooks EB, Fichtl RE, DeVecchio JL, Heinzel FP. Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis. Infect Immun. 2003 Nov; 71(11):6453-62. PMID: 14573667; PMCID: PMC219611.
    30. Murray HW, Brooks EB, DeVecchio JL, Heinzel FP. Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis. Antimicrob Agents Chemother. 2003 Aug; 47(8):2513-7. PMID: 12878513; PMCID: PMC166064.
    31. Murray HW, Moreira AL, Lu CM, DeVecchio JL, Matsuhashi M, Ma X, Heinzel FP. Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis. J Infect Dis. 2003 Aug 01; 188(3):458-64. PMID: 12870129.
      View in: PubMed
    32. Safdar A, Armstrong D, Murray HW. A novel defect in interferon-gamma secretion in patients with refractory nontuberculous pulmonary mycobacteriosis. Ann Intern Med. 2003 Mar 18; 138(6):521. PMID: 12639099.
      View in: PubMed
    33. Safdar A, White DA, Stover D, Armstrong D, Murray HW. Profound interferon gamma deficiency in patients with chronic pulmonary nontuberculous mycobacteriosis. Am J Med. 2002 Dec 15; 113(9):756-9. PMID: 12517367.
      View in: PubMed
    34. Murray HW. Kala-azar--progress against a neglected disease. N Engl J Med. 2002 Nov 28; 347(22):1793-4. PMID: 12456856.
      View in: PubMed
    35. Murray HW, Lu CM, Mauze S, Freeman S, Moreira AL, Kaplan G, Coffman RL. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect Immun. 2002 Nov; 70(11):6284-93. PMID: 12379707; PMCID: PMC130311.
    36. Sundar S, Sahu M, Mehta H, Gupta A, Kohli U, Rai M, Berman JD, Murray HW. Noninvasive management of Indian visceral leishmaniasis: clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit. Clin Infect Dis. 2002 Sep 01; 35(5):581-6. PMID: 12173133.
      View in: PubMed
    37. Sundar S, Pai K, Sahu M, Kumar V, Murray HW. Immunochromatographic strip-test detection of anti-K39 antibody in Indian visceral leishmaniasis. Ann Trop Med Parasitol. 2002 Jan; 96(1):19-23. PMID: 11989529.
      View in: PubMed
    38. Murray HW. Tissue granuloma structure-function in experimental visceral leishmaniasis. Int J Exp Pathol. 2001 Oct; 82(5):249-67. PMID: 11703536; PMCID: PMC2517779.
    39. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ. 2001 Aug 25; 323(7310):419-22. PMID: 11520836; PMCID: PMC37549.
    40. Murray HW. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother. 2001 Aug; 45(8):2185-97. PMID: 11451673; PMCID: PMC90630.
    41. Murray HW, Jungbluth A, Ritter E, Montelibano C, Marino MW. Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect Immun. 2000 Nov; 68(11):6289-93. PMID: 11035737; PMCID: PMC97711.
    42. Murray HW. Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine. Antimicrob Agents Chemother. 2000 Nov; 44(11):3235-6. PMID: 11036063; PMCID: PMC101643.
    43. Murray HW. Mononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intracellular adhesion molecule 1-dependent and -independent regulation. Infect Immun. 2000 Nov; 68(11):6294-9. PMID: 11035738; PMCID: PMC97712.
    44. Murray HW, Montelibano C, Peterson R, Sypek JP. Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis. J Infect Dis. 2000 Nov; 182(5):1497-502. PMID: 11023473.
      View in: PubMed
    45. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis. 2000 Oct; 31(4):1104-7. PMID: 11049798.
      View in: PubMed
    46. Sundar S, Makharia A, More DK, Agrawal G, Voss A, Fischer C, Bachmann P, Murray HW. Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis. 2000 Oct; 31(4):1110-3. PMID: 11049800.
      View in: PubMed
    47. Sundar S, Gupta LB, Rastogi V, Agrawal G, Murray HW. Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis. Trans R Soc Trop Med Hyg. 2000 Mar-Apr; 94(2):200-4. PMID: 10897369.
      View in: PubMed
    48. Murray HW, Pépin J, Nutman TB, Hoffman SL, Mahmoud AA. Tropical medicine. BMJ. 2000 Feb 19; 320(7233):490-4. PMID: 10678866; PMCID: PMC1127532.
    49. Murray HW, Delph-Etienne S. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. J Infect Dis. 2000 Feb; 181(2):795-9. PMID: 10669380.
      View in: PubMed
    50. Murray HW. Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches. Int J Infect Dis. 2000; 4(3):158-77. PMID: 11179920.
      View in: PubMed
    51. Murray HW, Delph-Etienne S. Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect Immun. 2000 Jan; 68(1):288-93. PMID: 10603400; PMCID: PMC97133.
    52. Sundar S, Gupta LB, Makharia MK, Singh MK, Voss A, Rosenkaimer F, Engel J, Murray HW. Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol. 1999 Sep; 93(6):589-97. PMID: 10707104.
      View in: PubMed
    53. Murray HW. Kala-azar as an AIDS-related opportunistic infection. AIDS Patient Care STDS. 1999 Aug; 13(8):459-65. PMID: 10800524.
      View in: PubMed
    54. Murray HW, Nathan CF. Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med. 1999 Feb 15; 189(4):741-6. PMID: 9989990; PMCID: PMC2192937.
    55. Sundar S, Goyal AK, Mandal AK, Makharia MK, Singh VP, Murray HW. Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis. J Assoc Physicians India. 1999 Feb; 47(2):186-8. PMID: 10999086.
      View in: PubMed
    56. Safdar A, Hartman BJ, Connor BA, Murray HW. Pulmonary edema in malaria. Int J Infect Dis. 1999; 3(4):217-9. PMID: 10575153.
      View in: PubMed
    57. Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A, Hilgard P, Murray HW. Trial of oral miltefosine for visceral leishmaniasis. Lancet. 1998 Dec 05; 352(9143):1821-3. PMID: 9851383.
      View in: PubMed
    58. Sundar S, Goyal AK, More DK, Singh MK, Murray HW. Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex. Ann Trop Med Parasitol. 1998 Oct; 92(7):755-64. PMID: 9924533.
      View in: PubMed
    59. Taylor AP, Murray HW. Therapeutic effect of interferon-gamma gene transfer in experimental visceral leishmaniasis. J Infect Dis. 1998 Sep; 178(3):908-11. PMID: 9728571.
      View in: PubMed
    60. Sundar S, Sinha PR, Agrawal NK, Srivastava R, Rainey PM, Berman JD, Murray HW, Singh VP. A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate. Am J Trop Med Hyg. 1998 Jul; 59(1):139-43. PMID: 9684642.
      View in: PubMed
    61. Sundar S, Kumar P, Makharia M, Goyal A, Rogers M, Gibbs D, Murray H. Atovaquone alone or with fluconazole as oral therapy for Indian kala-azar. Clin Infect Dis. 1998 Jul; 27(1):215-6. PMID: 9675482.
      View in: PubMed
    62. Kenney RT, Sacks DL, Gam AA, Murray HW, Sundar S. Splenic cytokine responses in Indian kala-azar before and after treatment. J Infect Dis. 1998 Mar; 177(3):815-8. PMID: 9498473.
      View in: PubMed
    63. Sundar S, Reed SG, Singh VP, Kumar PC, Murray HW. Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet. 1998 Feb 21; 351(9102):563-5. PMID: 9492776.
      View in: PubMed
    64. Sundar S, Singh VP, Sharma S, Makharia MK, Murray HW. Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. J Infect Dis. 1997 Oct; 176(4):1117-9. PMID: 9333181.
      View in: PubMed
    65. Sundar S, Agrawal NK, Sinha PR, Horwith GS, Murray HW. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med. 1997 Jul 15; 127(2):133-7. PMID: 9230003.
      View in: PubMed
    66. Murray HW. Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis. J Infect Dis. 1997 Jun; 175(6):1477-9. PMID: 9180189.
      View in: PubMed
    67. Sundar S, Reed SG, Sharma S, Mehrotra A, Murray HW. Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am J Trop Med Hyg. 1997 May; 56(5):522-5. PMID: 9180602.
      View in: PubMed
    68. Parkas V, Godwin J, Murray HW. Kala-azar comes to New York. Arch Intern Med. 1997 Apr 28; 157(8):921-3. PMID: 9129553.
      View in: PubMed
    69. Taylor AP, Murray HW. Intracellular antimicrobial activity in the absence of interferon-gamma: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-gamma gene-disrupted mice. J Exp Med. 1997 Apr 07; 185(7):1231-9. PMID: 9104810; PMCID: PMC2196266.
    70. Murray HW, Hariprashad J, Coffman RL. Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model. J Exp Med. 1997 Mar 03; 185(5):867-74. PMID: 9120392; PMCID: PMC2196164.
    71. Murray H, Clarke M, Locker D, Kay EJ. Reasons for tooth extractions in dental practices in Ontario, Canada according to tooth type. Int Dent J. 1997 Feb; 47(1):3-8. PMID: 9448782.
      View in: PubMed
    72. Stoeckle MY, Falck-Pederson E, Rubin BY, Anderson SL, Murray HW. Delivery of human interferon-gamma via gene transfer in vitro: prolonged expression and induction of macrophage antimicrobial activity. J Interferon Cytokine Res. 1996 Dec; 16(12):1015-9. PMID: 8974003.
      View in: PubMed
    73. Roberts WL, Hariprashad J, Rainey PM, Murray HW. Pentavalent antimony-mannan conjugate therapy of experimental visceral leishmaniasis. Am J Trop Med Hyg. 1996 Oct; 55(4):444-6. PMID: 8916804.
      View in: PubMed
    74. Murray HW. Current and future clinical applications of interferon-gamma in host antimicrobial defense. Intensive Care Med. 1996 Oct; 22 Suppl 4:S456-61. PMID: 8923089.
      View in: PubMed
    75. Sundar S, Singh VP, Agrawal NK, Gibbs DL, Murray HW. Treatment of kala-azar with oral fluconazole. Lancet. 1996 Aug 31; 348(9027):614. PMID: 8774589.
      View in: PubMed
    76. Murray H, Locker D, Kay EJ. Patterns of and reasons for tooth extractions in general dental practice in Ontario, Canada. Community Dent Oral Epidemiol. 1996 Jun; 24(3):196-200. PMID: 8871019.
      View in: PubMed
    77. Mannheimer SB, Hariprashad J, Stoeckle MY, Murray HW. Induction of macrophage antiprotozoal activity by monocyte chemotactic and activating factor. FEMS Immunol Med Microbiol. 1996 May; 14(1):59-61. PMID: 8804977.
      View in: PubMed
    78. Murray HW, Hariprashad J, Fichtl RE. Models of relapse of experimental visceral leishmaniasis. J Infect Dis. 1996 Apr; 173(4):1041-3. PMID: 8603949.
      View in: PubMed
    79. Murray HW, Hariprashad J. Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis. Antimicrob Agents Chemother. 1996 Mar; 40(3):586-7. PMID: 8851575; PMCID: PMC163162.
    80. Sundar S, Murray HW. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex. J Infect Dis. 1996 Mar; 173(3):762-5. PMID: 8627049.
      View in: PubMed
    81. Murray HW, Hariprashad J, McDermott DF, Stoeckle MY. Multiple host defense defects in failure of C57BL/6 ep/ep (pale ear) mice to resolve visceral Leishmania donovani infection. Infect Immun. 1996 Jan; 64(1):161-6. PMID: 8557335; PMCID: PMC173741.
    82. Sundar S, Murray HW. Effect of treatment with interferon-gamma alone in visceral leishmaniasis. J Infect Dis. 1995 Dec; 172(6):1627-9. PMID: 7594733.
      View in: PubMed
    83. Sundar S, Murray HW. Gamma interferon in the treatment of Kala-azar and other forms of Leishmaniasis. J Assoc Physicians India. 1995 May; 43(5):348-50. PMID: 9081967.
      View in: PubMed
    84. Murray HW, Hariprashad J, Aguero B, Arakawa T, Yeganegi H. Antimicrobial response of a T cell-deficient host to cytokine therapy: effect of interferon-gamma in experimental visceral leishmaniasis in nude mice. J Infect Dis. 1995 May; 171(5):1309-16. PMID: 7751708.
      View in: PubMed
    85. Sundar S, Rosenkaimer F, Lesser ML, Murray HW. Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis. J Infect Dis. 1995 Apr; 171(4):992-6. PMID: 7706829.
      View in: PubMed
    86. Murray HW, Squires KE, Weiss W, Sledz S, Sacks HS, Hassett J, Cross A, Anderson RE, Dunkle LM. Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089. J Infect Dis. 1995 Mar; 171 Suppl 2:S123-30. PMID: 7861017.
      View in: PubMed
    87. Murray HW, Cervia JS, Hariprashad J, Taylor AP, Stoeckle MY, Hockman H. Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis. J Clin Invest. 1995 Mar; 95(3):1183-92. PMID: 7883967; PMCID: PMC441456.
    88. Murray HW, Hariprashad J. Interleukin 12 is effective treatment for an established systemic intracellular infection: experimental visceral leishmaniasis. J Exp Med. 1995 Jan 01; 181(1):387-91. PMID: 7807019; PMCID: PMC2191839.
    89. Murray HW. Interferon-gamma and host antimicrobial defense: current and future clinical applications. Am J Med. 1994 Nov; 97(5):459-67. PMID: 7977435.
      View in: PubMed
    90. Sundar S, Rosenkaimer F, Murray HW. Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma. J Infect Dis. 1994 Sep; 170(3):659-62. PMID: 8077725.
      View in: PubMed
    91. Encarnacion CF, Giordano MF, Murray HW. Onchocerciasis in New York City. The Moa-Manhattan connection. Arch Intern Med. 1994 Aug 08; 154(15):1749-51. PMID: 8042892.
      View in: PubMed
    92. Midoneck SR, Richard J, Murray HW. Colorado tick fever in a resident of New York City. Arch Fam Med. 1994 Aug; 3(8):731-2. PMID: 7952262.
      View in: PubMed
    93. Tumang MC, Keogh C, Moldawer LL, Helfgott DC, Teitelbaum R, Hariprashad J, Murray HW. Role and effect of TNF-alpha in experimental visceral leishmaniasis. J Immunol. 1994 Jul 15; 153(2):768-75. PMID: 8021511.
      View in: PubMed
    94. Murray HW. Blood monocytes: differing effector role in experimental visceral versus cutaneous leishmaniasis. Parasitol Today. 1994 Jun; 10(6):220-3. PMID: 15275451.
      View in: PubMed
    95. Miralles GD, Stoeckle MY, McDermott DF, Finkelman FD, Murray HW. Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect Immun. 1994 Mar; 62(3):1058-63. PMID: 8112840; PMCID: PMC186224.
    96. Wallach FR, Forni AL, Hariprashad J, Stoeckle MY, Steinberg CR, Fisher L, Malawista SE, Murray HW. Circulating Borrelia burgdorferi in patients with acute Lyme disease: results of blood cultures and serum DNA analysis. J Infect Dis. 1993 Dec; 168(6):1541-3. PMID: 8018136.
      View in: PubMed
    97. Murray HW. Cytokines as antimicrobial therapy for the T cell-deficient patient: prospects for treatment of nonviral opportunistic infections. Clin Infect Dis. 1993 Nov; 17 Suppl 2:S407-13. PMID: 8274606.
      View in: PubMed
    98. Murray HW, Miralles GD, Stoeckle MY, McDermott DF. Role and effect of IL-2 in experimental visceral leishmaniasis. J Immunol. 1993 Jul 15; 151(2):929-38. PMID: 8335921.
      View in: PubMed
    99. Murray HW, Hariprashad J, Fichtl RE. Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine. Antimicrob Agents Chemother. 1993 Jul; 37(7):1504-5. PMID: 8363382; PMCID: PMC188002.
    100. Murray HW, Teitelbaum R, Hariprashad J. Response to treatment for an intracellular infection in a T cell-deficient host: toxoplasmosis in nude mice. J Infect Dis. 1993 May; 167(5):1173-7. PMID: 8486951.
      View in: PubMed
    101. Squires KE, Rosenkaimer F, Sherwood JA, Forni AL, Were JB, Murray HW. Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon-gamma. Am J Trop Med Hyg. 1993 May; 48(5):666-9. PMID: 8390795.
      View in: PubMed
    102. Cervia JS, Rosen H, Murray HW. Effector role of blood monocytes in experimental visceral leishmaniasis. Infect Immun. 1993 Apr; 61(4):1330-3. PMID: 8454335; PMCID: PMC281366.
    103. Wallach FR, Murray HW. Lymphocyte proliferation assay in Lyme disease. J Infect Dis. 1992 Oct; 166(4):938-9. PMID: 1527433.
      View in: PubMed
    104. Murray HW. The interferons, macrophage activation, and host defense against nonviral pathogens. J Interferon Res. 1992 Oct; 12(5):319-22. PMID: 1385553.
      View in: PubMed
    105. Winters RA, Murray HW. Malaria--the mime revisited: fifteen more years of experience at a New York City teaching hospital. Am J Med. 1992 Sep; 93(3):243-6. PMID: 1524074.
      View in: PubMed
    106. Miralles D, Hartman B, Brause B, Fisher L, Murray HW. Not everything that glitters is Lyme disease. Am J Med. 1992 Sep; 93(3):352-3. PMID: 1524093.
      View in: PubMed
    107. Squires KE, Brown ST, Armstrong D, Murphy WF, Murray HW. Interferon-gamma treatment for Mycobacterium avium-intracellular complex bacillemia in patients with AIDS. J Infect Dis. 1992 Sep; 166(3):686-7. PMID: 1500760.
      View in: PubMed
    108. Murray HW, Squires KE, Gassyuk-Botev E, DePamphilis JK. Interleukin-2 treatment, interferon-gamma induction, and AIDS monocyte activation. Am J Med. 1992 Aug; 93(2):234. PMID: 1497024.
      View in: PubMed
    109. Murray HW, Squires KE, Miralles CD, Stoeckle MY, Granger AM, Granelli-Piperno A, Bogdan C. Acquired resistance and granuloma formation in experimental visceral leishmaniasis. Differential T cell and lymphokine roles in initial versus established immunity. J Immunol. 1992 Mar 15; 148(6):1858-63. PMID: 1541824.
      View in: PubMed
    110. Murray HW, Teitelbaum RF. L-arginine-dependent reactive nitrogen intermediates and the antimicrobial effect of activated human mononuclear phagocytes. J Infect Dis. 1992 Mar; 165(3):513-7. PMID: 1538156.
      View in: PubMed
    111. Forni AL, Murray HW. Drug fever induced by heparin. Am J Med. 1992 Jan; 92(1):107. PMID: 1731499.
      View in: PubMed
    112. Murray HW, Granger AM, Teitelbaum RF. Gamma interferon-activated human macrophages and Toxoplasma gondii, Chlamydia psittaci, and Leishmania donovani: antimicrobial role of limiting intracellular iron. Infect Immun. 1991 Dec; 59(12):4684-6. PMID: 1937829; PMCID: PMC259098.
    113. Winters RA, Helfgott D, Storey-Johnson C, Murray HW. Human immunodeficiency virus infection and bacteremic meningococcal pneumonia. J Infect Dis. 1991 Jun; 163(6):1390. PMID: 2037806.
      View in: PubMed
    114. Murray HW, Granger AM, Mohanty SK. Response to chemotherapy in experimental visceral leishmaniasis: T cell-dependent but interferon-gamma- and interleukin-2-independent. J Infect Dis. 1991 Mar; 163(3):622-4. PMID: 1899875.
      View in: PubMed
    115. Squires KE, Kirsch M, Silverstein SC, Acosta A, McElrath MJ, Murray HW. Defect in the tissue cellular immune response: experimental visceral leishmaniasis in euthymic C57BL/6 ep/ep mice. Infect Immun. 1990 Dec; 58(12):3893-8. PMID: 2123825; PMCID: PMC313751.
    116. Cervia JS, Caputo TA, Davis SD, Murray HW. Septic pulmonary embolism complicating a central venous catheter. Chest. 1990 Dec; 98(6):1526. PMID: 2245701.
      View in: PubMed
    117. Salata RA, Martinez-Palomo A, Canales L, Murray HW, Trevino N, Ravdin JI. Suppression of T-lymphocyte responses to Entamoeba histolytica antigen by immune sera. Infect Immun. 1990 Dec; 58(12):3941-6. PMID: 2123828; PMCID: PMC313759.
    118. Murray HW. Gamma interferon, cytokine-induced macrophage activation, and antimicrobial host defense. In vitro, in animal models, and in humans. Diagn Microbiol Infect Dis. 1990 Sep-Oct; 13(5):411-21. PMID: 2126500.
      View in: PubMed
    119. Murray HW. Effect of continuous administration of interferon-gamma in experimental visceral leishmaniasis. J Infect Dis. 1990 May; 161(5):992-4. PMID: 2157773.
      View in: PubMed
    120. Naficy AB, Murray HW. Isolated meningitis caused by Blastoschizomyces capitatus. J Infect Dis. 1990 May; 161(5):1041-2. PMID: 2324536.
      View in: PubMed
    121. Cervia JS, Murray HW. Fungal cholecystitis and AIDS. J Infect Dis. 1990 Feb; 161(2):358. PMID: 2299216.
      View in: PubMed
    122. Murray HW. Interferon-gamma therapy in AIDS for mononuclear phagocyte activation. Biotherapy. 1990; 2(2):149-58. PMID: 2119203.
      View in: PubMed
    123. Squires KE, Schreiber RD, McElrath MJ, Rubin BY, Anderson SL, Murray HW. Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response. J Immunol. 1989 Dec 15; 143(12):4244-9. PMID: 2512353.
      View in: PubMed
    124. Jaffe EA, Armellino D, Lam G, Cordon-Cardo C, Murray HW, Evans RL. IFN-gamma and IFN-alpha induce the expression and synthesis of Leu 13 antigen by cultured human endothelial cells. J Immunol. 1989 Dec 15; 143(12):3961-6. PMID: 2512344.
      View in: PubMed
    125. Kelly CD, Russo CM, Rubin BY, Murray HW. Antigen-stimulated human interferon-gamma generation: role of accessory cells and their expressed or secreted products. Clin Exp Immunol. 1989 Sep; 77(3):397-402. PMID: 2553309; PMCID: PMC1542056.
    126. Murray HW, Godbold JH, Jurica KB, Roberts RB. Progression to AIDS in patients with lymphadenopathy or AIDS-related complex: reappraisal of risk and predictive factors. Am J Med. 1989 May; 86(5):533-8. PMID: 2565690.
      View in: PubMed
    127. Murray HW, Oca MJ, Granger AM, Schreiber RD. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J Clin Invest. 1989 Apr; 83(4):1253-7. PMID: 2539396; PMCID: PMC303815.
    128. Murray HW, Szuro-Sudol A, Wellner D, Oca MJ, Granger AM, Libby DM, Rothermel CD, Rubin BY. Role of tryptophan degradation in respiratory burst-independent antimicrobial activity of gamma interferon-stimulated human macrophages. Infect Immun. 1989 Mar; 57(3):845-9. PMID: 2492973; PMCID: PMC313187.
    129. Squires KE, Murphy WF, Madoff LC, Murray HW. Interferon-gamma and Mycobacterium avium-intracellulare infection. J Infect Dis. 1989 Mar; 159(3):599-600. PMID: 2492589.
      View in: PubMed
    130. Murray HW, Nathan CF. In vivo killing of intracellular visceral Leishmania donovani by a macrophage-targeted hydrogen peroxide-generating system. J Infect Dis. 1988 Dec; 158(6):1372-5. PMID: 3198943.
      View in: PubMed
    131. Stern JJ, Hartman BJ, Sharkey P, Rowland V, Squires KE, Murray HW, Graybill JR. Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. Am J Med. 1988 Oct; 85(4):477-80. PMID: 2845778.
      View in: PubMed
    132. Murray HW, Scavuzzo DA, Kelly CD, Rubin BY, Roberts RB. T4+ cell production of interferon gamma and the clinical spectrum of patients at risk for and with acquired immunodeficiency syndrome. Arch Intern Med. 1988 Jul; 148(7):1613-6. PMID: 3132901.
      View in: PubMed
    133. Murray HW, DePamphilis J, Schooley RT, Hirsch MS. Circulating interferon gamma in AIDS patients treated with interleukin-2. N Engl J Med. 1988 06 09; 318(23):1538-9. PMID: 3130575.
      View in: PubMed
    134. Stern JJ, Oca MJ, Rubin BY, Anderson SL, Murray HW. Role of L3T4+ and LyT-2+ cells in experimental visceral leishmaniasis. J Immunol. 1988 Jun 01; 140(11):3971-7. PMID: 3131421.
      View in: PubMed
    135. McElrath MJ, Murray HW, Cohn ZA. The dynamics of granuloma formation in experimental visceral leishmaniasis. J Exp Med. 1988 Jun 01; 167(6):1927-37. PMID: 3290381; PMCID: PMC2189681.
    136. Murray HW, Scavuzzo DA, Chaparas SD, Roberts RB. T lymphocyte responses to mycobacterial antigen in AIDS patients with disseminated Mycobacterium avium-Mycobacterium intracellulare infection. Chest. 1988 May; 93(5):922-5. PMID: 3129241.
      View in: PubMed
    137. Murray HW, Berman JD, Wright SD. Immunochemotherapy for intracellular Leishmania donovani infection: gamma interferon plus pentavalent antimony. J Infect Dis. 1988 May; 157(5):973-8. PMID: 2834469.
      View in: PubMed
    138. Murray HW. Interferon-gamma, the activated macrophage, and host defense against microbial challenge. Ann Intern Med. 1988 Apr; 108(4):595-608. PMID: 3126690.
      View in: PubMed
    139. Murray HW. Survival of intracellular pathogens within human mononuclear phagocytes. Semin Hematol. 1988 Apr; 25(2):101-11. PMID: 3133769.
      View in: PubMed
    140. Yoshida R, Murray HW, Nathan CF. Agonist and antagonist effects of interferon alpha and beta on activation of human macrophages. Two classes of interferon gamma receptors and blockade of the high-affinity sites by interferon alpha or beta. J Exp Med. 1988 Mar 01; 167(3):1171-85. PMID: 2965208; PMCID: PMC2188875.
    141. Murray HW. Macrophage activation in the acquired immunodeficiency syndrome. Adv Exp Med Biol. 1988; 239:297-307. PMID: 3059771.
      View in: PubMed
    142. Weinberg DS, Murray HW. Coping with AIDS. The special problems of New York City. N Engl J Med. 1987 Dec 03; 317(23):1469-73. PMID: 3120006.
      View in: PubMed
    143. Kelly CD, Welte K, Murray HW. Antigen-induced human interferon-gamma production. Differential dependence on interleukin 2 and its receptor. J Immunol. 1987 Oct 01; 139(7):2325-8. PMID: 2958545.
      View in: PubMed
    144. Roberts RB, Laskin OL, Laurence J, Scavuzzo D, Murray HW, Kim YT, Connor JD. Ribavirin pharmacodynamics in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther. 1987 Oct; 42(4):365-73. PMID: 2444379.
      View in: PubMed
    145. Murray HW, Jacobs JL, Bovbjerg DH. Accessory cell function of AIDS monocytes. J Infect Dis. 1987 Oct; 156(4):696. PMID: 3624915.
      View in: PubMed
    146. Stern JJ, Murray HW. In vitro granuloma formation in experimental visceral leishmaniasis. J Infect Dis. 1987 Sep; 156(3):533-4. PMID: 3497212.
      View in: PubMed
    147. McElrath MJ, Murray HW, Cohn ZA. The local cellular immune response in experimental leishmaniasis. Ann Inst Pasteur Immunol. 1987 Sep-Oct; 138(5):787-90. PMID: 3440063.
      View in: PubMed
    148. Salata RA, Murray HW, Rubin BY, Ravdin JI. The role of gamma interferon in the generation of human macrophages cytotoxic for Entamoeba histolytica trophozoites. Am J Trop Med Hyg. 1987 Jul; 37(1):72-8. PMID: 2886071.
      View in: PubMed
    149. Murray HW, Scavuzzo D, Jacobs JL, Kaplan MH, Libby DM, Schindler J, Roberts RB. In vitro and in vivo activation of human mononuclear phagocytes by interferon-gamma. Studies with normal and AIDS monocytes. J Immunol. 1987 Apr 15; 138(8):2457-62. PMID: 3104467.
      View in: PubMed
    150. Murray HW, Stern JJ, Welte K, Rubin BY, Carriero SM, Nathan CF. Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma. J Immunol. 1987 Apr 01; 138(7):2290-7. PMID: 3104456.
      View in: PubMed
    151. Murray HW, Carriero SM, Donelly DM. Presence of a macrophage-mediated suppressor cell mechanism during cell-mediated immune response in experimental visceral leishmaniasis. Infect Immun. 1986 Nov; 54(2):487-93. PMID: 2945788; PMCID: PMC260187.
    152. Rothermel CD, Rubin BY, Jaffe EA, Murray HW. Oxygen-independent inhibition of intracellular Chlamydia psittaci growth by human monocytes and interferon-gamma-activated macrophages. J Immunol. 1986 Jul 15; 137(2):689-92. PMID: 3088106.
      View in: PubMed
    153. Murray HW, Gellene RA, Libby DM, Rothermel CD, Rubin BY. Activation of tissue macrophages from AIDS patients: in vitro response of AIDS alveolar macrophages to lymphokines and interferon-gamma. J Immunol. 1985 Oct; 135(4):2374-7. PMID: 3928746.
      View in: PubMed
    154. Lepay DA, Steinman RM, Nathan CF, Murray HW, Cohn ZA. Liver macrophages in murine listeriosis. Cell-mediated immunity is correlated with an influx of macrophages capable of generating reactive oxygen intermediates. J Exp Med. 1985 Jun 01; 161(6):1503-12. PMID: 4009118; PMCID: PMC2187641.
    155. Lepay DA, Nathan CF, Steinman RM, Murray HW, Cohn ZA. Murine Kupffer cells. Mononuclear phagocytes deficient in the generation of reactive oxygen intermediates. J Exp Med. 1985 May 01; 161(5):1079-96. PMID: 3921651; PMCID: PMC2187591.
    156. Murray HW, Spitalny GL, Nathan CF. Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma. J Immunol. 1985 Mar; 134(3):1619-22. PMID: 3918107.
      View in: PubMed
    157. Murray HW, Rubin BY, Carriero SM, Harris AM, Jaffee EA. Human mononuclear phagocyte antiprotozoal mechanisms: oxygen-dependent vs oxygen-independent activity against intracellular Toxoplasma gondii. J Immunol. 1985 Mar; 134(3):1982-8. PMID: 2981929.
      View in: PubMed
    158. Jacobs JL, Gold JW, Murray HW, Roberts RB, Armstrong D. Salmonella infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1985 Feb; 102(2):186-8. PMID: 3881072.
      View in: PubMed
    159. Murray HW, Rubin BY, Carriero S, Acosta AM. Reversible defect in antigen-induced lymphokine and gamma-interferon generation in cutaneous leishmaniasis. J Immunol. 1984 Oct; 133(4):2250-4. PMID: 6432909.
      View in: PubMed
    160. Nathan CF, Prendergast TJ, Wiebe ME, Stanley ER, Platzer E, Remold HG, Welte K, Rubin BY, Murray HW. Activation of human macrophages. Comparison of other cytokines with interferon-gamma. J Exp Med. 1984 Aug 01; 160(2):600-5. PMID: 6206183; PMCID: PMC2187443.
    161. Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, Shelhamer J, Lane HC, Urmacher C, Honig C, Longo DL, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984 May; 100(5):663-71. PMID: 6231873.
      View in: PubMed
    162. Murray HW, Rubin BY, Masur H, Roberts RB. Impaired production of lymphokines and immune (gamma) interferon in the acquired immunodeficiency syndrome. N Engl J Med. 1984 Apr 05; 310(14):883-9. PMID: 6422299.
      View in: PubMed
    163. Murray HW, Rubin BY, Rothermel CD. Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine. J Clin Invest. 1983 Oct; 72(4):1506-10. PMID: 6415111; PMCID: PMC370435.
    164. Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med. 1983 Sep 01; 158(3):670-89. PMID: 6411853; PMCID: PMC2187114.
    165. Murray HW, Byrne GI, Rothermel CD, Cartelli DM. Lymphokine enhances oxygen-independent activity against intracellular pathogens. J Exp Med. 1983 Jul 01; 158(1):234-9. PMID: 6864162; PMCID: PMC2187079.
    166. Murray HW, Cartelli DM. Killing of intracellular Leishmania donovani by human mononuclear phagocytes. Evidence for oxygen-dependent and -independent leishmanicidal activity. J Clin Invest. 1983 Jul; 72(1):32-44. PMID: 6308049; PMCID: PMC1129158.
    167. Szuro-Sudol A, Murray HW, Nathan CF. Suppression of macrophage antimicrobial activity by a tumor cell product. J Immunol. 1983 Jul; 131(1):384-7. PMID: 6408180.
      View in: PubMed
    168. Murray HW. How protozoa evade intracellular killing. Ann Intern Med. 1983 Jun; 98(6):1016-8. PMID: 6344706.
      View in: PubMed
    169. Murray HW. Cell-mediated immune response in experimental visceral leishmaniasis. II. Oxygen-dependent killing of intracellular Leishmania donovani amastigotes. J Immunol. 1982 Jul; 129(1):351-7. PMID: 6282967.
      View in: PubMed
    170. Murray HW, Masur H, Keithly JS. Cell-mediated immune response in experimental visceral leishmaniasis. I. Correlation between resistance to Leishmania donovani and lymphokine-generating capacity. J Immunol. 1982 Jul; 129(1):344-50. PMID: 7086136.
      View in: PubMed
    171. Scott WA, Pawlowski NA, Murray HW, Andreach M, Zrike J, Cohn ZA. Regulation of arachidonic acid metabolism by macrophage activation. J Exp Med. 1982 Apr 01; 155(4):1148-60. PMID: 6801185; PMCID: PMC2186658.
    172. Masur H, Murray HW, Jones TC. Effect of hydrocortisone on macrophage response to lymphokine. Infect Immun. 1982 Feb; 35(2):709-14. PMID: 7056582; PMCID: PMC351099.
    173. Murray HW. Interaction of Leishmania with a macrophage cell line. Correlation between intracellular killing and the generation of oxygen intermediates. J Exp Med. 1981 Jun 01; 153(6):1690-5. PMID: 7252424; PMCID: PMC2186195.
    174. Murray HW. Susceptibility of Leishmania to oxygen intermediates and killing by normal macrophages. J Exp Med. 1981 May 01; 153(5):1302-15. PMID: 7252418; PMCID: PMC2186145.
    175. Murray HW, Brandstetter RD, Lavyne MH. Ventriculoatrial shunting for hydrocephalus complicating tuberculous meningitis. Am J Med. 1981 Apr; 70(4):895-8. PMID: 7211924.
      View in: PubMed
    176. Nathan CF, Arrick BA, Murray HW, DeSantis NM, Cohn ZA. Tumor cell anti-oxidant defenses. Inhibition of the glutathione redox cycle enhances macrophage-mediated cytolysis. J Exp Med. 1981 Apr 01; 153(4):766-82. PMID: 7252413; PMCID: PMC2186135.
    177. Murray HW, Cohn ZA. Macrophage oxygen-dependent antimicrobial activity. III. Enhanced oxidative metabolism as an expression of macrophage activation. J Exp Med. 1980 Dec 01; 152(6):1596-609. PMID: 6256463; PMCID: PMC2186036.
    178. Murray HW, Nathan CF, Cohn ZA. Macrophage oxygen-dependent antimicrobial activity. IV. Role of endogenous scavengers of oxygen intermediates. J Exp Med. 1980 Dec 01; 152(6):1610-24. PMID: 7452149; PMCID: PMC2186026.
    179. Murray HW, Cohn ZA. Mononuclear phagocyte antimicrobial and antitumor activity: the role of oxygen intermediates. J Invest Dermatol. 1980 May; 74(5):285-8. PMID: 7391600.
      View in: PubMed
    180. Murray HW, Juangbhanich CW, Nathan CF, Cohn ZA. Macrophage oxygen-dependent antimicrobial activity. II. The role of oxygen intermediates. J Exp Med. 1979 Oct 01; 150(4):950-64. PMID: 512587; PMCID: PMC2185678.
    181. Murray HW, Cohn ZA. Macrophage oxygen-dependent antimicrobial activity. I. Susceptibility of Toxoplasma gondii to oxygen intermediates. J Exp Med. 1979 Oct 01; 150(4):938-49. PMID: 92521; PMCID: PMC2185675.
    182. Murray HW, Ellis GC, Blumenthal DS, Sos TA. Fever and pulmonary thromboembolism. Am J Med. 1979 Aug; 67(2):232-5. PMID: 463928.
      View in: PubMed
    183. Murray HW. Antimicrobial therapy in pulmonary aspiration. Am J Med. 1979 Feb; 66(2):188-90. PMID: 425963.
      View in: PubMed
    184. Soave R, Murray HW, Litrenta MM. Bacterial invasion of pulmonary vessels. Pseudomonas bacteremia mimicking pulmonary thromboembolism with infarction. Am J Med. 1978 Nov; 65(5):864-7. PMID: 707544.
      View in: PubMed
    185. Murray HW, Romankiewicz JA, Masur H. Septic bursitis. Ann Intern Med. 1978 Oct; 89(4):576. PMID: 697247.
      View in: PubMed
    186. Masur H, Murray HW, Roberts RB. Nafcillin therapy for Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1978 Sep; 14(3):457-61. PMID: 708023; PMCID: PMC352481.
    187. Murray HW, Gross KC, Masur H, Roberts RB. Serious infections caused by Streptococcus milleri. Am J Med. 1978 May; 64(5):759-64. PMID: 645741.
      View in: PubMed
    188. Murray HW, Knox DL, Green WR, Susel RM. Cytomegalovirus retinitis in adults. A manifestation of disseminated viral infection. Am J Med. 1977 Oct; 63(4):574-84. PMID: 199061.
      View in: PubMed
    189. Murray HW, Mann JJ, Genecin A, McKusick VA. Fever with dissecting aneurysm of the aorta. Am J Med. 1976 Jul; 61(1):140-4. PMID: 937367.
      View in: PubMed
    190. Keren DF, Rawlings W, Murray HW, Leonard WR. Arizona hinshawii osteomyelitis with antecedent enteric fever and sepsis. A case report with a review of the literature. Am J Med. 1976 Apr; 60(4):577-82. PMID: 1274993.
      View in: PubMed
    191. Murray HW, Fialk MA, Roberts RB. Candida arthritis. A manifestation of disseminated candidiasis. Am J Med. 1976 Apr; 60(4):587-95. PMID: 1274995.
      View in: PubMed
    192. Wigley FM, Murray HW, Mann RB, Saba GP, Kashima H, Mann JJ. Unusual manifestation of tuberculosis: TE fistula. Am J Med. 1976 Feb; 60(2):310-4. PMID: 766627.
      View in: PubMed
    193. Murray HW, Mann JJ. Letter: "Goalpost fever". Ann Intern Med. 1975 Jul; 83(1):84-5. PMID: 1147445.
      View in: PubMed
    194. Murray HW, Masur H, Senterfit LB, Roberts RB. The protean manifestations of Mycoplasma pneumoniae infection in adults. Am J Med. 1975 Feb; 58(2):229-42. PMID: 163580.
      View in: PubMed
    195. Fialk MA, Murray HW. Letter: Cardiac Munchausen syndrome. Ann Intern Med. 1974 Oct; 81(4):562. PMID: 4414136.
      View in: PubMed
    196. Murray HW, Littman ML, Roberts RB. Disseminated paracoccidioidomycosis (South American blastomycosis) in the United States. Am J Med. 1974 Feb; 56(2):209-20. PMID: 4590780.
      View in: PubMed
    Murray's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description